Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.47−0.02 (-4.78%)
Close on Nov 13, 2026Market cap $131.40MP/E –Yield –
Akebia Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Akebia Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 78.9%. For fiscal 2025 it was 83.3%, against 60.6% the year before. The highest annual figure on record is 96.3% in fiscal 2018.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.3% | +22.7 |
| FY2024 | Dec 31, 2024 | 60.6% | −1.3 |
| FY2023 | Dec 31, 2023 | 61.9% | −8.8 |
| FY2022 | Dec 31, 2022 | 70.7% | +41.9 |
| FY2021 | Dec 31, 2021 | 28.8% | +29.4 |
| FY2020 | Dec 31, 2020 | -0.6% | −57.2 |
| FY2019 | Dec 31, 2019 | 56.6% | −39.6 |
| FY2018 | Dec 31, 2018 | 96.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 82.8% | −1.3 |
| Q2 FY2026 | Jun 30, 2026 | 78.8% | −5.3 |
| Q1 FY2026 | Mar 31, 2026 | 77.0% | −9.7 |
| Q4 FY2025 | Dec 31, 2025 | 78.2% | +22.0 |
| Q3 FY2025 | Sep 30, 2025 | 84.0% | +21.9 |
| Q2 FY2025 | Jun 30, 2025 | 84.1% | +23.2 |
| Q1 FY2025 | Mar 31, 2025 | 86.7% | +22.3 |
| Q4 FY2024 | Dec 31, 2024 | 56.2% | −10.6 |
| Q3 FY2024 | Sep 30, 2024 | 62.2% | +5.0 |
| Q2 FY2024 | Jun 30, 2024 | 60.9% | −8.4 |
| Q1 FY2024 | Mar 31, 2024 | 64.4% | +14.9 |
| Q4 FY2023 | Dec 31, 2023 | 66.8% | +9.1 |
| Q3 FY2023 | Sep 30, 2023 | 57.2% | +35.8 |
| Q2 FY2023 | Jun 30, 2023 | 69.3% | −15.9 |
| Q1 FY2023 | Mar 31, 2023 | 49.5% | −13.0 |
| Q4 FY2022 | Dec 31, 2022 | 57.7% | +40.3 |
| Q3 FY2022 | Sep 30, 2022 | 21.4% | −45.9 |
| Q2 FY2022 | Jun 30, 2022 | 85.3% | +84.5 |
| Q1 FY2022 | Mar 31, 2022 | 62.6% | +28.7 |
| Q4 FY2021 | Dec 31, 2021 | 17.4% | +30.3 |
| Q3 FY2021 | Sep 30, 2021 | 67.3% | +17.9 |
| Q2 FY2021 | Jun 30, 2021 | 0.8% | +94.5 |
| Q1 FY2021 | Mar 31, 2021 | 33.8% | −34.8 |
| Q4 FY2020 | Dec 31, 2020 | -12.8% | −58.0 |
| Q3 FY2020 | Sep 30, 2020 | 49.4% | −9.0 |
| Q2 FY2020 | Jun 30, 2020 | -93.7% | −156.3 |
| Q1 FY2020 | Mar 31, 2020 | 68.7% | +11.7 |
| Q4 FY2019 | Dec 31, 2019 | 45.2% | −41.9 |
| Q3 FY2019 | Sep 30, 2019 | 58.4% | – |
| Q2 FY2019 | Jun 30, 2019 | 62.6% | – |
| Q1 FY2019 | Mar 31, 2019 | 57.0% | – |
| Q4 FY2018 | Dec 31, 2018 | 87.0% | – |
See a number that looks wrong?